• 제목/요약/키워드: Cognitive Disorder

검색결과 458건 처리시간 0.024초

쿠마린 유도체의 아세틸콜린 에스테라제 저해활성 연구 (Study on the Acetylcholinesterase Inhibitory Activity of Coumarin Derivatives)

  • 남승옥;윤용돈;박동현;류종훈;이용섭
    • 약학회지
    • /
    • 제55권6호
    • /
    • pp.473-477
    • /
    • 2011
  • Alzheimer's disease (AD), one of the most common forms of dementia, is a progressive neurodegenerative disorder symptomatically characterized by the decline in memory and cognitive abilities. To date, the successful therapeutic strategy to treat AD is to maintain the levels of acetylcholine (ACh) by inhibiting acetylcholinesterase (AChE) to lead five drugs in clinical use. In this study, several coumarin derivatives were designed based on the lead structure of scopoletin and evaluated for their AChE inhibitory activities.

정신병리아동 부모의 자아분화, 가족기능 관한 연구 (Self-Differentiation and Family Function in Parents of Children with Psychopathology)

  • 황규선;최연실
    • 아동학회지
    • /
    • 제23권6호
    • /
    • pp.65-79
    • /
    • 2002
  • The present study surveyed both the parents of 130 children with psychopathology and the parents of 240 normal children. children were between 2 and 12 years of age. No differences were found between parents in self-differentiation or in family function by type of disorder. Parents of children with psychopathology were lower than parents of normal children in self-differentiation; this was particularly evident in cognitive function-emotional function, and emotional cut-off. Patents of children with psychopathology were lower than parents of normal children in terms of family function. Multiple regression analyses indicated that parent's self-differentiation, children's psychopathology, and parent's education level had a significant influence on family function. The regression model explained 52% of the variance.

  • PDF

노인에서의 수면 호흡 장애 (Sleep-Related Breathing Disorders in the Elderly)

  • 신철
    • 수면정신생리
    • /
    • 제8권1호
    • /
    • pp.11-17
    • /
    • 2001
  • In 2000, the number of people aged 65 and over increased to 3.37 million, accounting for 7.1% of the total population of South Korea. The elderly population will increase up to 19.3% in 2030. Sleep disordered breathing (SDB) seems to increase with age. More than 50-60% of old people complain of SDB-related signs and symptoms including awakening headache, excessive daytime sleepiness, fatigue, cognitive dysfunction, memory loss, personality changes, and depression. The influence of a mild degree of SDB upon the elderly is unclear, but moderate to severe SDB is well known to be associated with many diseases including hypertension, arrhythmia, myocardial infarction, stroke, dementia, and sudden death. Therefore, physicians should pay attention to elderly patients who complain of SDB related symptoms and signs that may not be normal signs of aging. Physicians need to become more sensitive to treat SDB in the elderly.

  • PDF

Aberrant phosphorylation in the pathogenesis of Alzheimer's disease

  • Chung, Sul-Hee
    • BMB Reports
    • /
    • 제42권8호
    • /
    • pp.467-474
    • /
    • 2009
  • The modification of proteins by reversible phosphorylation is a key mechanism in the regulation of various physiological functions. Abnormal protein kinase or phosphatase activity can cause disease by altering the phosphorylation of critical proteins in normal cellular and disease processes. Alzheimer' disease (AD), typically occurring in the elderly, is an irreversible, progressive brain disorder characterized by memory loss and cognitive decline. Accumulating evidence suggests that protein kinase and phosphatase activity are altered in the brain tissue of AD patients. Tau is a highly recognized phosphoprotein that undergoes hyperphosphorylation to form neurofibrillary tangles, a neuropathlogical hallmark with amyloid plaques in AD brains. This study is a brief overview of the altered protein phosphorylation pathways found in AD. Understanding the molecular mechanisms by which the activities of protein kinases and phosphatases are altered as well as the phosphorylation events in AD can potentially reveal novel insights into the role aberrant phosphorylation plays in the pathogenesis of AD, providing support for protein phosphorylation as a potential treatment strategy for AD.

Beta-amyloid imaging in dementia

  • Chun, Kyung Ah
    • Journal of Yeungnam Medical Science
    • /
    • 제35권1호
    • /
    • pp.1-6
    • /
    • 2018
  • Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta ($A{\beta}$), in the brain. Although the precise mechanism underlying the neurotoxicity of $A{\beta}$ has not been established, $A{\beta}$ accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the $A{\beta}$ burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as $^{11}C$-labeled Pittsburgh Compound B or $^{18}F$-labeled tracers, such as $^{18}F$-florbetaben, $^{18}F$-florbetapir, and $^{18}F$-flutemetamol, which bind to $A{\beta}$ deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of $A{\beta}$ throughout the brain in living subjects. $A{\beta}$ imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies.

Effects and mechanisms of a mindfulness-based intervention on insomnia

  • Kim, Hye-Geum
    • Journal of Yeungnam Medical Science
    • /
    • 제38권4호
    • /
    • pp.282-288
    • /
    • 2021
  • Medication alone is not sufficient to treat insomnia. In addition, the side effects of sleep medications themselves cannot be ignored during treatment. Insomnia begins with poor sleep quality and discomfort, but as it continues, patients fall into a vicious circle of insomnia with negative thoughts and dysfunctional and distorted perceptions related to sleep. Mindfulness-based intervention for insomnia corrects these sequential cognitive and behavioral processes. The mindfulness technique basically recognizes all the thoughts, feelings, and experiences that occur to us as they are, nonjudgmentally, and then trains them to return to the senses of our body. In this way, while noticing all the processes of the sequential vicious cycle and training them to return to our bodies (e.g., breathing), mindfulness determines whether we are really sleepy or just fatigued. This mindfulness-based intervention can be a useful nonpharmaceutical intervention for insomnia, and its stability and efficacy has been proven by many studies.

Understanding insomnia as systemic disease

  • Yun, Seokho;Jo, Sohye
    • Journal of Yeungnam Medical Science
    • /
    • 제38권4호
    • /
    • pp.267-274
    • /
    • 2021
  • Sleep plays a critical role in homeostasis of the body and mind. Insomnia is a disease that causes disturbances in the initiation and maintenance of sleep. Insomnia is known to affect not only the sleep process itself but also an individual's cognitive function and emotional regulation during the daytime. It increases the risk of various neuropsychiatric diseases such as depression, anxiety disorder, and dementia. Although it might appear that insomnia only affects the nervous system, it is also a systemic disease that affects several aspects of the body, such as the cardiovascular, endocrine, and immune systems; therefore, it increases the risk of various diseases such as hypertension, diabetes mellitus, and infection. Insomnia has a wide range of effects on our bodies because sleep is a complex and active process. However, a high proportion of patients with insomnia do not seek treatment, which results in high direct and indirect costs. This is attributed to the disregard of many of the negative effects of insomnia. Therefore, we expect that understanding insomnia as a systemic disease will provide an opportunity to understand the condition better and help prevent secondary impairment due to insomnia.

Growth Hormone Therapy in Children with Prader-Willi Syndrome

  • Im, Minji
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제5권1호
    • /
    • pp.34-38
    • /
    • 2021
  • Prader-Willi syndrome is a complicated genetic disorder caused by a mutation on chromosome 15q11-13. The disease results in morbid obesity due to hyperphagia, growth disturbance, multiple endocrine problems from hypopituitarism, developmental delay, and cognitive or behavioral problems. Recombinant human growth hormone has been used to improve body composition and muscle mass, which plays a main role in treating patients with Prader-Willi syndrome. We describe previous studies showing the efficacy and safety of growth hormone treatment in children with Prader-Willi syndrome and provide treatment guidelines. Growth hormone therapy could be beneficial for children with Prader-Willi syndrome and improve their quality of life.

Adrenomyeloneuropathy with cerebral involvement due to a novel frameshift variant in ABCD1 gene

  • Kim, Hye Weon;Kim, Hyunjin;Jeong, Dongyoung;Chung, Kyuyoon;Lee, Eun-Jae;Lim, Young-Min;Kim, Kwang-Kuk
    • Annals of Clinical Neurophysiology
    • /
    • 제23권1호
    • /
    • pp.61-64
    • /
    • 2021
  • Adrenoleukodystrophy (ALD) is the most common peroxisomal disorder caused by mutations in the gene, ABCD1, causing abnormal accumulation of very-long-chain fatty acids in the nervous system and adrenal glands. There are various clinical manifestations of ALD. Here we report a 47-year-old male with adrenomyeloneuropathy with cerebral involvement who exhibited progressive gait disturbance and cognitive impairment. A novel frameshift variant (c.95del [p.Val32Alafs*36]) in exon 1 of ABCD1 was identified. This report provides additional information regarding the various clinical characteristics of ALD.

치료저항성 조현병: 정의와 임상양상 (Treatment-Resistant Schizophrenia: Terminology and Clinical Features)

  • 이건석
    • 대한조현병학회지
    • /
    • 제23권2호
    • /
    • pp.45-50
    • /
    • 2020
  • Schizophrenia is one of serious mental illnesses and is often described as a heterogeneous disorder. Approximately one-third of schizophrenia cases are treatment-resistant schizophrenia (TRS). The aim of this study was to review the definitions and clinical features of TRS. Though it was found that the criteria for TRS were considerably diverse, the Treatment Response and Resistance in Psychosis (TRRIP) consensus criteria were recently introduced. According to the TRRIP criteria, TRS should be suspected if symptoms persist alongside psychotic symptoms despite sufficient treatment for ≥12 weeks, or two or more symptoms persist significantly for ≥6 weeks. The clinical characteristics of TRS includes an earlier age of onset, more severe and familial form, possibly more rural residence, unlikely association with male sex, and an increase in cognitive deficits.